Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 20.0% in December

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 7,600 shares, a drop of 20.0% from the November 30th total of 9,500 shares. Based on an average trading volume of 24,000 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

Wall Street Analyst Weigh In

NERV has been the topic of several research reports. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th. StockNews.com started coverage on Minerva Neurosciences in a research report on Saturday. They set a “sell” rating on the stock.

Minerva Neurosciences Price Performance

Shares of NASDAQ NERV traded up $0.03 during trading hours on Monday, reaching $2.29. The stock had a trading volume of 29,654 shares, compared to its average volume of 50,468. The company has a market cap of $16.01 million, a price-to-earnings ratio of -5.20 and a beta of 0.11. Minerva Neurosciences has a twelve month low of $2.06 and a twelve month high of $13.49. The business’s fifty day moving average is $2.28 and its two-hundred day moving average is $2.69.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.